Stay updated on Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial page.

Latest updates to the Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial page
- Check5 days agoChange DetectedThe ClinicalTrials.gov record for the paclitaxel and pembrolizumab study is displayed with its study design, eligibility criteria, outcome measures, record dates, and associated documents.SummaryDifference55%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe ClinicalTrials.gov footer now shows revision v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check26 days agoChange DetectedA banner announces NIH website transition updates and says that “Super Intelligence” may appear in place of “Artificial Intelligence” across NIH content.SummaryDifference1%

- Check33 days agoChange DetectedThe footer’s site revision identifier changes from v3.7.1 to v3.7.2. The page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check40 days agoChange DetectedThe footer’s site revision identifier changes from v3.7.0 to v3.7.1, while the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check53 days agoChange DetectedThe study page now shows a 403 Forbidden error with a minimal header and a Home link. Most study-related content and navigational elements are absent on this page, indicating the record is not currently accessible.SummaryDifference20%

Stay in the know with updates to Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Paclitaxel and Pembrolizumab in Refractory Urothelial Cancer Clinical Trial page.